title: The need for effective pancreatic cancer detection and management: a biomarker-based strategy.
abstract: Pancreatic cancer (Pa) is generally a very aggressive disease, with few effective approaches available for early diagnosis or therapy. These factors, combined with the aggressiveness and chemoresistance of Pa, results in a bleak outcome post-diagnosis. Cancer-related biomarkers have established capabilities for diagnosis, prognosis and screening and can be exploited to aid in earlier less-invasive diagnosis and optimization of targeted therapies. Pa has only one US FDA-approved biomarker, CA19-9, which has significant limitations. Hence, it is vital that novel biomarkers are identified and validated to diagnose, treat, control and monitor Pa. This review focuses on existing and potential Pa-associated markers and discusses how they may be applied in cohort for improved management of Pa.
authors.affiliation: a 1 School of Biotechnology, Dublin City University, Dublin 9, Ireland.
authors.forename: Aoife S
authors.initials: AS
authors.lastname: Crawley
authors.affiliation: a 1 School of Biotechnology, Dublin City University, Dublin 9, Ireland.|b 2 Biomedical Diagnostics Institute, National Centre for Sensor Research, Dublin City University, Dublin 9, Ireland.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: O'Kennedy
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D021441:Carcinoma, Pancreatic Ductal / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D019468:Disease Management; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D011379:Prognosis; D017422:Sequence Analysis, DNA
chemical_list: D014408:Biomarkers, Tumor
keywords: CA19-9; biomarkers; diagnostics; pancreatic cancer; therapeutics; tumor